West Pharmaceutical Services (WST) Q1 2026 Earnings
West Pharmaceutical Services reported Q1 2026 revenue of $844.9M (+21.0% YoY), beat analyst consensus of $780.3M by $64.6M. Diluted EPS came in at $2.13 (+46.9% YoY), beat the $1.68 consensus by $0.45. West Pharmaceutical Services reports across 2 business segments, led by Proprietary Products and Contract-Manufactured Products.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about West Pharmaceutical Services's Q1 2026 earnings report.
West Pharmaceutical Services (WST) reported Q1 2026 earnings on April 23, 2026 before market open.
West Pharmaceutical Services reported revenue of $844.9M and diluted EPS of $2.13 for Q1 2026.
Revenue beat the consensus estimate of $780.3M by $64.6M. EPS beat the consensus estimate of $1.68 by $0.45.
Compared to the same quarter a year prior, revenue grew 21.0% from $698.0M a year earlier and diluted EPS grew 46.9% from $1.45.
You can read the 8-K earnings release (0000105770-26-000047) and the 10-Q periodic report (0000105770-26-000049) directly on SEC EDGAR. The filing index links above go to sec.gov.